EpiCept reports Q3 loss, touts drug approval
-
- November
- 7
EpiCept Corp., an early-stage Eastview pharmaceutical company, reported this morning that it lost $6.2 million, or 9 cents a share, in the third quarter, compared with a loss of $7.7 million, or 20 cents a share, last year.
Jack Talley, the president and chief executive of EpiCept, said the company focused during the quarter on getting regulatory approval in Europe to market Ceplene, a drug to prevent the relapse of a form of leukemia. The company got the approval last month.
“We have carefully controlled expenses this year in all areas of company operations,†he said. “Having secured European approval of Ceplene, the next key iutem has been advancing partnership dialogues for Ceplene marketing rights and preparing for a commercial launch as soon as possible in 2009.â€
This entry was posted
on Friday, November 7th, 2008 at 9:32 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Category: Earnings season
Print
| 
Email
